Bulgaria · Delayed Price · Currency is BGN Sopharma AD Statistics
Total Valuation
Sopharma AD has a market cap or net worth of BGN 1.38 billion. The enterprise value is 2.01 billion.
| Market Cap | 1.38B |
| Enterprise Value | 2.01B |
Important Dates
The last earnings date was Saturday, August 30, 2025.
| Earnings Date | Aug 30, 2025 |
| Ex-Dividend Date | Jul 10, 2025 |
Share Statistics
Sopharma AD has 510.90 million shares outstanding. The number of shares has increased by 5.20% in one year.
| Current Share Class | 510.90M |
| Shares Outstanding | 510.90M |
| Shares Change (YoY) | +5.20% |
| Shares Change (QoQ) | +0.78% |
| Owned by Insiders (%) | 9.94% |
| Owned by Institutions (%) | 0.54% |
| Float | 126.96M |
Valuation Ratios
The trailing PE ratio is 13.28.
| PE Ratio | 13.28 |
| Forward PE | n/a |
| PS Ratio | 0.57 |
| PB Ratio | 1.49 |
| P/TBV Ratio | 2.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 43.55 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.21, with an EV/FCF ratio of -372.57.
| EV / Earnings | 19.60 |
| EV / Sales | 0.83 |
| EV / EBITDA | 10.21 |
| EV / EBIT | 14.88 |
| EV / FCF | -372.57 |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 0.67.
| Current Ratio | 1.30 |
| Quick Ratio | 0.68 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 3.94 |
| Debt / FCF | -115.95 |
| Interest Coverage | 5.68 |
Financial Efficiency
Return on equity (ROE) is 12.55% and return on invested capital (ROIC) is 4.43%.
| Return on Equity (ROE) | 12.55% |
| Return on Assets (ROA) | 3.50% |
| Return on Invested Capital (ROIC) | 4.43% |
| Return on Capital Employed (ROCE) | 8.08% |
| Revenue Per Employee | 409,217 |
| Profits Per Employee | 17,369 |
| Employee Count | 5,599 |
| Asset Turnover | 1.40 |
| Inventory Turnover | 4.49 |
Taxes
In the past 12 months, Sopharma AD has paid 14.46 million in taxes.
| Income Tax | 14.46M |
| Effective Tax Rate | 11.65% |
Stock Price Statistics
The stock price has increased by +35.38% in the last 52 weeks. The beta is -0.15, so Sopharma AD's price volatility has been lower than the market average.
| Beta (5Y) | -0.15 |
| 52-Week Price Change | +35.38% |
| 50-Day Moving Average | 2.55 |
| 200-Day Moving Average | 2.16 |
| Relative Strength Index (RSI) | 65.00 |
| Average Volume (20 Days) | 54,513 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sopharma AD had revenue of BGN 2.41 billion and earned 102.39 million in profits. Earnings per share was 0.20.
| Revenue | 2.41B |
| Gross Profit | 532.96M |
| Operating Income | 96.79M |
| Pretax Income | 124.06M |
| Net Income | 102.39M |
| EBITDA | 137.65M |
| EBIT | 96.79M |
| Earnings Per Share (EPS) | 0.20 |
Balance Sheet
The company has 34.55 million in cash and 624.49 million in debt, giving a net cash position of -589.94 million or -1.15 per share.
| Cash & Cash Equivalents | 34.55M |
| Total Debt | 624.49M |
| Net Cash | -589.94M |
| Net Cash Per Share | -1.15 |
| Equity (Book Value) | 926.37M |
| Book Value Per Share | 1.75 |
| Working Capital | 231.19M |
Cash Flow
In the last 12 months, operating cash flow was 31.80 million and capital expenditures -37.18 million, giving a free cash flow of -5.39 million.
| Operating Cash Flow | 31.80M |
| Capital Expenditures | -37.18M |
| Free Cash Flow | -5.39M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 22.09%, with operating and profit margins of 4.01% and 4.24%.
| Gross Margin | 22.09% |
| Operating Margin | 4.01% |
| Pretax Margin | 5.14% |
| Profit Margin | 4.24% |
| EBITDA Margin | 5.71% |
| EBIT Margin | 4.01% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 1.91%.
| Dividend Per Share | 0.05 |
| Dividend Yield | 1.91% |
| Dividend Growth (YoY) | -68.18% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 27.13% |
| Buyback Yield | -5.20% |
| Shareholder Yield | -3.28% |
| Earnings Yield | 7.40% |
| FCF Yield | -0.39% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 10, 2025. It was a forward split with a ratio of 3.
| Last Split Date | Jul 10, 2025 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Sopharma AD has an Altman Z-Score of 2.61 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.61 |
| Piotroski F-Score | 5 |